WallStSmart

Becton Dickinson and Company (BDX)vsRepro Med Systems Inc (KRMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 49745% more annual revenue ($22.48B vs $45.11M). BDX leads profitability with a 4.2% profit margin vs -4.0%. BDX earns a higher WallStSmart Score of 52/100 (C-).

BDX

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.49

KRMD

Avoid

26

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 0.98
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+11.1%)

Margin of Safety

+11.1%

Fair Value

$203.14

Current Price

$177.85

$25.29 discount

UndervaluedFair: $203.14Overvalued

Intrinsic value data unavailable for KRMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

KRMD2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
18.2%8/10

18.2% revenue growth

Areas to Watch

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
31.2x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
4.2%3/10

4.2% margin — thin

EPS GrowthGrowth
-31.4%2/10

Earnings declined 31.4%

KRMD4 concerns · Avg: 3.0/10
Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Market CapQuality
$147.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-13.5%2/10

ROE of -13.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : KRMD

The strongest argument for KRMD centers on Debt/Equity, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin. Thin 4.2% margins leave little buffer for downturns.

Bear Case : KRMD

The primary concerns for KRMD are Price/Book, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

BDX profiles as a value stock while KRMD is a growth play — different risk/reward profiles.

KRMD carries more volatility with a beta of 0.45 — expect wider price swings.

KRMD is growing revenue faster at 18.2% — sustainability is the question.

BDX generates stronger free cash flow (509M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (52/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Repro Med Systems Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.

Want to dig deeper into these stocks?